NASDAQ:OCGN

Ocugen Stock Insider Trading

Healthcare > Biotechnology

Buy OCGN

*Your capital is at risk

$1.30

-0.0400 (-2.99%)

At Close: Jun 03, 2026

Ocugen Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.31. In total, the insiders bought 22.66M and sold 888.27K OCGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.31
● Buy	22.66M shares
● Sell	888.27K shares
84% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jan 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.31. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 14, 2024 Buy	Common Stock	Ramachandran Ramesh Chief Accounting Officer	Officer	0 Value: $0
Sep 16, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	842 Value: $985
Sep 16, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	842 Value: $985
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Whittington Marna C Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Kompella Uday Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Castillo Kirsten Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Zhang Junge Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Fernandes Prabhavathi Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Fernandes Prabhavathi Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Zhang Junge Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Castillo Kirsten Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Kompella Uday Director	Director	66 929 Value: $103.7K
Jun 28, 2024 Buy	Option (Right to Buy) A-Award	Whittington Marna C Director	Director	66 929 Value: $103.7K
Jun 17, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	917 Value: $1K
Jun 17, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	917 Value: $1K
Apr 16, 2024 Buy	Option (Right to Buy) A-Award	Qamar Huma Chief Medical Officer	Officer	308 465 Value: $490.5K
Apr 16, 2024 Buy	Option (Right to Buy) A-Award	Qamar Huma Chief Medical Officer	Officer	308 465 Value: $490.5K
Mar 18, 2024 Buy	Common Stock	Qamar Huma Chief Medical Officer	Officer	0 Value: $0
Mar 18, 2024 Buy	Common Stock	Qamar Huma Chief Medical Officer	Officer	0 Value: $0
Jan 03, 2024 Sell	Common Stock F-InKind	Musunuri Shankar Chief Executive Officer	CEO / President	180 204 Value: $117.7K
Jan 03, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	41 633 Value: $27.2K
Jan 03, 2024 Sell	Common Stock F-InKind	Upadhyay Arun See Remarks	Officer	41 633 Value: $27.2K
Jan 03, 2024 Sell	Common Stock F-InKind	Musunuri Shankar Chief Executive Officer	CEO / President	180 204 Value: $117.7K
Jan 02, 2024 Buy	Option (Right to Buy) A-Award	Musunuri Shankar Chief Executive Officer	CEO / President	492 126 Value: $323.6K
Jan 02, 2024 Buy	Option (Right to Buy) A-Award	Upadhyay Arun See Remarks	Officer	137 795 Value: $90.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OCUGEN INC

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...

Read Full Profile Here